AGL 40.00 Decreased By ▼ -0.01 (-0.02%)
AIRLINK 127.00 Decreased By ▼ -0.99 (-0.77%)
BOP 6.68 Increased By ▲ 0.08 (1.21%)
CNERGY 4.49 Decreased By ▼ -0.11 (-2.39%)
DCL 8.60 Increased By ▲ 0.12 (1.42%)
DFML 41.30 Decreased By ▼ -0.18 (-0.43%)
DGKC 86.71 Increased By ▲ 0.13 (0.15%)
FCCL 32.16 Increased By ▲ 0.02 (0.06%)
FFBL 64.70 Decreased By ▼ -0.72 (-1.1%)
FFL 10.29 Increased By ▲ 0.04 (0.39%)
HUBC 109.51 Decreased By ▼ -0.98 (-0.89%)
HUMNL 14.90 Increased By ▲ 0.15 (1.02%)
KEL 5.05 Decreased By ▼ -0.08 (-1.56%)
KOSM 7.40 Increased By ▲ 0.28 (3.93%)
MLCF 41.39 Decreased By ▼ -0.26 (-0.62%)
NBP 60.60 Increased By ▲ 0.51 (0.85%)
OGDC 190.00 Decreased By ▼ -4.69 (-2.41%)
PAEL 27.81 Decreased By ▼ -0.14 (-0.5%)
PIBTL 7.75 Decreased By ▼ -0.25 (-3.13%)
PPL 149.75 Decreased By ▼ -1.42 (-0.94%)
PRL 26.73 Decreased By ▼ -0.15 (-0.56%)
PTC 16.18 Increased By ▲ 0.18 (1.13%)
SEARL 86.02 Increased By ▲ 7.82 (10%)
TELE 7.72 Increased By ▲ 0.33 (4.47%)
TOMCL 35.58 Decreased By ▼ -0.09 (-0.25%)
TPLP 8.14 Increased By ▲ 0.23 (2.91%)
TREET 16.51 Increased By ▲ 0.62 (3.9%)
TRG 53.35 Increased By ▲ 0.59 (1.12%)
UNITY 26.28 Decreased By ▼ -0.27 (-1.02%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 9,884 Decreased By -36.4 (-0.37%)
BR30 30,600 Decreased By -151.5 (-0.49%)
KSE100 93,355 Increased By 130.9 (0.14%)
KSE30 28,931 Increased By 46 (0.16%)

NEW DELHI: The Serum Institute of India (SII), the world’s biggest vaccine maker, has developed the country’s first cervical cancer shot that will hit the market soon, the company and the government said on Thursday.

Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020, according to the World Health Organization. About 90% of the new cases and deaths worldwide occurred in low- and middle-income countries that year.

Two human papillomavirus (HPV) types, 16 and 18, are responsible for at least 70% of cervical cancers, and India’s Department of Biotechnology said the Indian vaccine would work on HPV types 16 and 18, as well as 6 and 11.

Merck & Co and GSK Plc are the main makers of HPV vaccines.

“The indigenously developed vaccine will make our country self-sufficient in curbing female mortality caused by cervical cancer,” SII Chief Executive Adar Poonawalla said in a statement.

WHO reports more than 41,000 cases of monkeypox globally

He told reporters the vaccine would be out for sale in a few months, first for the Indian market and then the world. It may be priced between 200 rupees and 400 rupees ($2.51-$5.03) and the company will aim to produce about 200 million doses in two years, Reuters partner ANI cited Poonawalla as saying.

The vaccine will be administered via injection in two doses among 9-14 year olds and in three doses for those between 15 and 26.

Comments

Comments are closed.